BRPI0412659A - isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto - Google Patents
isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido compostoInfo
- Publication number
- BRPI0412659A BRPI0412659A BRPI0412659-9A BRPI0412659A BRPI0412659A BR PI0412659 A BRPI0412659 A BR PI0412659A BR PI0412659 A BRPI0412659 A BR PI0412659A BR PI0412659 A BRPI0412659 A BR PI0412659A
- Authority
- BR
- Brazil
- Prior art keywords
- cci
- isomer
- pharmaceutical
- compound
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
"ISÈMERO C DE CCI-779, SEU PROCESSO DE PREPARAçãO, COMPOSIçãO FARMACêUTICA COMPREENDENDO O MESMO E PACOTE FARMACêUTICO CONTENDO O REFERIDO COMPOSTO". O isómero C de CCI-779 purificado é fornecido, assim como são as composições farmacêuticas e kits contendo o mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48771203P | 2003-07-16 | 2003-07-16 | |
| PCT/US2004/021580 WO2005010010A1 (en) | 2003-07-16 | 2004-07-06 | Cci-779 isomer c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412659A true BRPI0412659A (pt) | 2006-09-26 |
Family
ID=34102717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412659-9A BRPI0412659A (pt) | 2003-07-16 | 2004-07-06 | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7074804B2 (pt) |
| EP (1) | EP1646635A1 (pt) |
| JP (1) | JP2007522091A (pt) |
| CN (1) | CN1823073A (pt) |
| AU (1) | AU2004259669A1 (pt) |
| BR (1) | BRPI0412659A (pt) |
| CA (1) | CA2528173A1 (pt) |
| MX (1) | MXPA06000407A (pt) |
| WO (1) | WO2005010010A1 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1389209B1 (en) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| KR20040106547A (ko) * | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
| RU2344821C2 (ru) | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| US7601332B2 (en) | 2003-01-27 | 2009-10-13 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| JP2008530090A (ja) | 2005-02-09 | 2008-08-07 | ワイス | Cci−779多形及びその使用 |
| JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なcci−779製剤 |
| AU2006218918A1 (en) | 2005-03-02 | 2006-09-08 | Wyeth | Purification of rapamycin |
| BRPI0607390A2 (pt) | 2005-03-02 | 2017-08-22 | Wyeth Corp | Processo para recuperar cci-779 de licores mâe |
| AU2006221024A1 (en) | 2005-03-07 | 2006-09-14 | Wyeth | Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin |
| CN101175757B (zh) * | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | 蝶酸及其缀合物的合成和纯化 |
| RU2470668C2 (ru) * | 2005-08-19 | 2012-12-27 | Эндосайт, Инк. | Конъюгаты лиганда с несколькими лекарственными средствами |
| JP2009504783A (ja) * | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
| AR058282A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
| JP2009520818A (ja) * | 2005-12-20 | 2009-05-28 | ワイス | 薬物物質不純物の制御によるcci−779製剤安定性の制御 |
| US20070203171A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same |
| US7622477B2 (en) * | 2006-02-28 | 2009-11-24 | Cordis Corporation | Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same |
| US20070225313A1 (en) * | 2006-02-28 | 2007-09-27 | Zhao Jonathon Z | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| WO2008065887A1 (en) * | 2006-11-27 | 2008-06-05 | Terumo Kabushiki Kaisha | Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative |
| US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| CN104127878A (zh) * | 2007-03-14 | 2014-11-05 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| EP2209374B1 (en) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysins and processes for preparing |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| EA201590622A1 (ru) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения |
| WO2017053222A1 (en) | 2015-09-24 | 2017-03-30 | Drexel University | Novel compositions and methods for treating or preventing dermal disorders |
| WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
| EP3788050B1 (en) | 2018-05-01 | 2024-08-28 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
| PL3788049T3 (pl) | 2018-05-01 | 2023-06-19 | Revolution Medicines, Inc. | Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR |
| EP4531859A4 (en) | 2022-05-25 | 2026-05-27 | Revolution Medicines Inc | CANCER TREATMENT METHODS USING AN MTOR INHIBITOR |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935110B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| US6399625B1 (en) * | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) * | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
-
2004
- 2004-07-06 EP EP04777600A patent/EP1646635A1/en not_active Withdrawn
- 2004-07-06 MX MXPA06000407A patent/MXPA06000407A/es active IP Right Grant
- 2004-07-06 CN CNA2004800201927A patent/CN1823073A/zh not_active Withdrawn
- 2004-07-06 WO PCT/US2004/021580 patent/WO2005010010A1/en not_active Ceased
- 2004-07-06 BR BRPI0412659-9A patent/BRPI0412659A/pt not_active IP Right Cessation
- 2004-07-06 AU AU2004259669A patent/AU2004259669A1/en not_active Withdrawn
- 2004-07-06 JP JP2006520213A patent/JP2007522091A/ja not_active Withdrawn
- 2004-07-06 CA CA002528173A patent/CA2528173A1/en not_active Abandoned
- 2004-07-12 US US10/889,247 patent/US7074804B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050014777A1 (en) | 2005-01-20 |
| JP2007522091A (ja) | 2007-08-09 |
| MXPA06000407A (es) | 2006-03-17 |
| EP1646635A1 (en) | 2006-04-19 |
| WO2005010010A1 (en) | 2005-02-03 |
| AU2004259669A1 (en) | 2005-02-03 |
| CA2528173A1 (en) | 2005-02-03 |
| US7074804B2 (en) | 2006-07-11 |
| CN1823073A (zh) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| SE0300119D0 (sv) | Novel compounds | |
| MXPA06000407A (es) | Isomero c cci-779. | |
| WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| BRPI0409227A (pt) | composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto | |
| BR0210464A (pt) | Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| EA200601007A1 (ru) | 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы | |
| SE0302139D0 (sv) | Novel compounds | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| BRPI0417157A (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| SE0303280D0 (sv) | Novel compounds | |
| WO2005055943A3 (en) | Vinorelbine derivatives | |
| EE05182B1 (et) | Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| ATE373000T1 (de) | Pyrazolopyridin-derivate als antiherpesmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |